Foundayo Cost: Self-Pay, Commercial Savings and Medicare Bridge
Foundayo is the orforglipron tablet. Its cost depends on dose, insurance and the specific savings pathway. The current manufacturer page provides a more useful starting point than an unsupported list-price estimate or the assumption that every patient pays the same amount. For more on this topic, see our guide to foundayo vs wegovy.
Current manufacturer self-pay offers
On October 27, 2026, LillyDirect listed 30-day self-pay starting prices of $149 for 0.8 mg and 2.5 mg,$199 for 5.5 mg, and $299 for 9 mg. The 2.5 mg and 5.5 mg promotions are temporarily reduced through December 31, 2026. The 14.5 mg and 17.2 mg $299 rates require the Self-Pay Journey Program and a refill within 45 days; regular prices apply otherwise. Prescription, eligibility, taxes/fees and full terms matter.
Commercial savings are conditional
Eligible commercially insured patients with Foundayo coverage may pay as little as $25 monthly under the manufacturer offer. Government beneficiaries are excluded from that commercial card. This is not insurance, an unconditional cap, or proof that an employer plan covers obesity medication. Check the current full terms and actual adjudicated amount.
The $50 Medicare pathway is the Bridge
CMS’s Medicare GLP-1 Bridge is a temporary program outside ordinary Part D benefit payments, running July 1, 2026 through December 31, 2027. Foundayo is among its named products for eligible patients. The $50 monthly copay does not count toward Part D out-of-pocket spending. It is not a universal $50 Part D formulary price, and Medicaid eligibility follows separate rules.
Compare dose-specific real prices
Compare the dose and 30-day supply actually prescribed, physician/program fees, offer expiration, refill conditions and your real covered amount. Foundayo is not automatically cheaper than every injectable or oral GLP-1: brand offers, covered copays and doses differ. A list-price comparison is not a patient-cost ranking.
Why price cannot be inferred from chemistry
Orforglipron is a small molecule rather than a peptide. That distinction does not independently establish Lilly’s manufacturing cost, margin or reason for a particular price. This review has no audited cost data showing how much a production saving was passed on to patients. Future price changes remain uncertain. Our overview of peptide safety explains how to read uncertainty around benefits and risks.
Check the applicable pathway before paying
Confirm the named prescription and dose with the clinician, then compare eligible manufacturer terms and insurance or Bridge options. Keep a copy of the applicable terms and refill deadline. This review does not establish your eligibility or authorize a dose change to qualify for a price.
Related reading
- Foundayo guide
- orforglipron overview
- Wegovy
- Zepbound
- prior authorization
- semaglutide without insurance
- tirzepatide without insurance
- Foundayo vs Zepbound
- Foundayo vs Wegovy
- which GLP-1 is best for weight loss
- orforglipron side effects
- Foundayo Guide
Full drug profile.
- Orforglipron Side Effects
What to expect.
- Foundayo vs Zepbound
Pill vs injection.
- GLP-1 Insurance Coverage
Getting it covered.
Frequently Asked Questions
Current LillyDirect self-pay starts at $149 for selected doses, with higher-dose and refill conditions. Eligible commercial coverage can qualify for an as-low-as $25 offer; eligible Medicare patients may use the separate $50 Bridge. There is no single price for everyone.
Use the current dose-specific LillyDirect schedule and your coverage result. Selected $149/$199 promotional doses and $299 higher-dose offers have conditions; visit and program fees may be separate.
Not universally. Compare actual prescribed dose, supply, coverage and current manufacturer offers rather than list prices. No blanket cash-price superiority is established.
Check the exact plan formulary and prior-authorization criteria for Foundayo. Coverage of another obesity medicine does not establish coverage of this one.
The current manufacturer page describes an as-low-as $25 offer for eligible commercially insured patients with Foundayo coverage. Government beneficiaries are excluded; full terms and savings limits govern.
The Medicare GLP-1 Bridge began July 1, 2026 and includes Foundayo for eligible beneficiaries at $50 monthly, outside normal Part D benefit payments. This is not automatic coverage for every person enrolled in Part D.
LillyDirect offers prescription-required self-pay pricing subject to product, dose and program conditions. No insurance does not mean no clinical evaluation or unrestricted access.
Orforglipron is a small molecule tablet, but manufacturing cost and company pricing rationale are not independently established here. Patient cost must be checked from actual offers.
Future prices cannot be reliably predicted from competition or tablet manufacturing alone. Recheck manufacturer terms, plan coverage and the applicable dose at each renewal.